The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
Open accessAbstract
Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis. Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics. Direct and indirect inhibition of the JAKs, with small molecule inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clinical measures of disease, consistent with their respective preclinical experiments. Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities. INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations <50 nM. Significant efficacy, as assessed by improvements in clinical, histologic and radiographic signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3. Diminution of inflammatory Th1 and Th17 associated cytokine mRNA levels was observed in the draining lymph nodes of treated rats. INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematologic effects. These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models. Clinical evaluation of INCB028050 in RA is ongoing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation
Murphy, C. A., Langrish, C. L., Chen, Y., Blumenschein, W., McClanahan, T., Kastelein, R. A., Sedgwick, J. D., & Cua, D. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030896 · Cited by 1,669
Brand, D. D., Latham, K. A., & Rosloniec, E. F. (2007) · Nature Protocols · doi:10.1038/nprot.2007.173 · Cited by 1,418
Smolen, J. S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399
Parham, C., Chirica, M., Timans, J., Vaisberg, E., Travis, M., Cheung, J., Pflanz, S., Zhang, R., Singh, K. P., Vega, F., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5699 · Cited by 1,296
Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice
Nakae, S., Nambu, A., Sudo, K., & Iwakura, Y. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6173 · Cited by 1,273
Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors
Parganas, E., Wang, D., Stravopodis, D., Topham, D. J., Marine, J.-C., Teglund, S., Vanin, E. F., Bodner, S., Colamonici, O. R., van Deursen, J. M., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81167-8 · Cited by 1,156
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis
Neubauer, H., Cumano, A., Müller, M., Wu, H., Huffstadt, U., & Pfeffer, K. (1998) · Cell · doi:10.1016/s0092-8674(00)81168-x · Cited by 914
Lubberts, E., Koenders, M. I., Oppers‐Walgreen, B., van den Bersselaar, L., Coenen‐de Roo, C. J. J., Joosten, L. A. B., & van den Berg, W. B. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20001 · Cited by 709
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Changelian, P. S., Flanagan, M. E., Ball, D. J., Kent, C. R., Magnuson, K. S., Martin, W. H., Rizzuti, B. J., Sawyer, P. S., Perry, B. D., Brissette, W. H., et al. (2003) · Science · doi:10.1126/science.1087061 · Cited by 607
Interleukin 6 is required for the development of collagen-induced arthritis
Alonzi, T., Fattori, E., Lazzaro, D., Costa, P., Probert, L., Kollias, G., De Benedetti, F., Poli, V., & Ciliberto, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.461 · Cited by 604
Guschin, D., Rogers, N., Briscoe, J., Witthuhn, B., Watling, D., Horn, F., Pellegrini, S., Yasukawa, K., Heinrich, P., & Stark, G. R. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07128.x · Cited by 433
A new modality for immunosuppression: targeting the JAK/STAT pathway
O'Shea, J. J., Pesu, M., Borie, D. C., & Changelian, P. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1441 · Cited by 303
Young, D. A., Hegen, M., Ma, H. L. M., Whitters, M. J., Albert, L. M., Lowe, L., Senices, M., Wu, P. W., Sibley, B., Leathurby, Y., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22452 · Cited by 275
Williams, N. K., Bamert, R. S., Patel, O., Wang, C., Walden, P. M., Wilks, A. F., Fantino, E., Rossjohn, J., & Lucet, I. S. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.01.041 · Cited by 270
Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis
Takagi, N., Mihara, M., Moriya, Y., Nishimoto, N., Yoshizaki, K., Kishimoto, T., Takeda, Y., & Ohsugi, Y. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2117::aid-art6>3.0.co;2-p · Cited by 270
Targeting interleukin‐15 in patients with rheumatoid arthritis: A proof‐of‐concept study
Baslund, B., Tvede, N., Danneskiold‐Samsoe, B., Larsson, P., Panayi, G., Petersen, J., Petersen, L. J., Beurskens, F. J. M., Schuurman, J., van de Winkel, J. G. J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21249 · Cited by 265
Bush, K. A., Farmer, K. M., Walker, J. S., & Kirkham, B. W. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10173 · Cited by 252
Therapeutic targeting of Janus kinases
Pesu, M., Laurence, A., Kishore, N., Zwillich, S. H., Chan, G., & O'Shea, J. J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00644.x · Cited by 231
Kagari, T., Doi, H., & Shimozato, T. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.3.1459 · Cited by 207
Collagen antibody-induced arthritis
Khachigian, L. M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.393 · Cited by 195
Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344
Brodmerkel, C. M., Huber, R., Covington, M., Diamond, S., Hall, L., Collins, R., Leffet, L., Gallagher, K., Feldman, P., Collier, P., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5370 · Cited by 186
Self-citationCartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
Milici, A. J., Kudlacz, E. M., Audoly, L., Zwillich, S. H., & Changelian, P. S. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2365 · Cited by 142
Cytokine networks—towards new therapies for rheumatoid arthritis
McInnes, I. B., & Liew, F. Y. (2005) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0020 · Cited by 138
Jiang, J., Ghoreschi, K., Deflorian, F., Chen, Z. J., Perreira, M., Pesu, M., Smith, J. A., Nguyễn, Ð.-T., Liu, E. H., Leister, W., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801142b · Cited by 131
Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells
Penard‐Lacronique, V., Boureux, A., Monni, R., Dumon, S., Mauchauffé, M., Mayeux, P., Gouilleux, F., Berger, R., Gisselbrecht, S., Ghysdael, J., et al. (2000) · Blood · doi:10.1182/blood.v95.6.2076 · Cited by 130
Cytokines that regulate autoimmunity
Diveu, C., McGeachy, M. J., & Cua, D. J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.09.003 · Cited by 94
TheJanusprotein tyrosine kinases in hematopoietic cytokine signaling
Ihle, J. N. (1995) · Seminars in Immunology · doi:10.1006/smim.1995.0029 · Cited by 69
Verstovšek, S., Kantarjian, H. M., Pardanani, A. D., Thomas, D. A., Cortes, J. E., Mesa, R. A., Redman, J. R., Staschen, C., Fridman, J. S., Vaddi, K., et al. (2007) · Blood · doi:10.1182/blood.v110.11.558.558 · Cited by 45
Self-citation
Cited by
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
O'Shea, J. J., & Plenge, R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.014 · Cited by 1,138
The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010
Xu, M., Tchkonia, T., Ding, H., Ogrodnik, M., Lubbers, E. R., Pirtskhalava, T., White, T. A., Johnson, K. O., Stout, M. B., Mezera, V., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515386112 · Cited by 915
The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells
Seif, F., Khoshmirsafa, M., Aazami, H., Mohsenzadegan, M., Sedighi, G., & Bahar, M. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0177-y · Cited by 768
Marconi, V. C., Ramanan, A. V., de Bono, S., Kartman, C. E., Krishnan, V., Liao, R., Piruzeli, M. L. B., Goldman, J. D., Alatorre-Alexander, J., de Cassia Pellegrini, R., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00331-3 · Cited by 695
Metadata
- Authors
- Fridman, J. S., Scherle, P. A., Collins, R., Burn, T. C., Li, Y., Li, J., Covington, M. B., Thomas, B., Collier, P., Favata, M. F., Wen, X., Shi, J., McGee, R., Haley, P. J., Shepard, S., Rodgers, J. D., Yeleswaram, S., Hollis, G., Newton, R. C., Metcalf, B., Friedman, S. M., & Vaddi, K.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-05-01
- Volume
- 184
- Issue
- 9
- Pages
- 5298-5307
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2163087340
- Cited by
- 463
- References
- 29
- FWCI
- 13.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.